BioSpace News Archive

Ferring published its 2023 Annual Report showing the company’s annual revenues were €2.2 billion, a decrease of -4% on the previous year at actual exchange rates, but an increase of +1% at constant exchange rates.

Essential Pharma announces that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd.

Innate Pharma SA announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.

Brenus Pharma unveils groundbreaking results during the American Association Cancer Research (AACR) Annual meeting 2024 – San Diego (April 5-10).

NANO-X IMAGING LTD announced a new collaboration to advance the Nanox.ARC 3D imaging system and Nanox artificial intelligence solutions in Korea with AhealthZ – a distributor of healthcare services and devices – and SCL Science, AhealthZ’s affiliated company and subsidiary of global healthcare group SCL.

Scilex Holding Company announced launching of co-pay programs for both ZTlido® and ELYXYB® with the out-of-pocket costs for its product portfolio for commercially insured patients capped at $25 monthly, with certain eligible patients paying as low as $0.

HealthTrackRx, the nation’s premier molecular diagnostic testing laboratory, announced the appointment of Steven Goldberg, MD, MBA, as its Chief Medical Officer.

Cadrenal Therapeutics, Inc. announced that the United States Food and Drug Administration has granted tecarfarin Orphan Drug Designation for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device.

Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications announces the launch of its new multiplex spatial biology assay services for rapid, whole-slide imaging and analysis of tissue sections at subcellular resolution.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the presentation of a poster during the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5 through 10 in San Diego.